Next Article in Journal
Insidious-Onset Indurated Plaques on the Shins
Previous Article in Journal
How to Deal with Skin Biopsy in an Infant with Blisters?

5-Hydroxymethylcytosine Loss in Conjunctival Melanoma

Jules-Gonin Eye Hospital, Lausanne University, 1004 Lausanne, Switzerland
Experimental Pathology, University Hospital of Lausanne (CHUV), 1011 Lausanne, Switzerland
Dermatopathology Unit, Dermatology and Clinical Pathology Departments, University Hospitals of Geneva, 1205 Geneva, Switzerland
Author to whom correspondence should be addressed.
Academic Editor: Franco Rongioletti
Received: 22 April 2021 / Revised: 28 May 2021 / Accepted: 2 June 2021 / Published: 5 June 2021
(This article belongs to the Section Clinico-Pathological Correlation in Dermatopathology)
Aims: Conjunctival and cutaneous melanoma partially share similar clinical and molecular backgrounds. As 5-hydroxymethylcytosine (5-hmC) loss has been demonstrated in cutaneous melanoma, we decided to assess if similar changes were occurring in conjunctival melanoma. Methods: 5-methylcytosine (5-mC), 5-hmC and TET2 were respectively identified by immunohistochemistry and RNA ISH in 40 conjunctival nevi and 37 conjunctival melanomas. Clinicopathological correlations were established. Results: 5-mC, TET2 and 5-hmC were respectively identified in 67.5%, 95% and 100% of conjunctival nevi and in 81.1%, 35.1% and 54% of conjunctival melanomas. A significant 5-hmC and TET2 loss was identified in conjunctival melanoma comparing to nevus, as well as a significant correlation between TET2 and 5-hmC expression. In the melanomas, 5-hmC expression was only significantly associated with local lymphatic invasion, but not with other clinicopathological parameters. There was a correlation between TET2 expression and the localization of the tumors. 5-mC expression was not associated with any clinicopathological parameters. Conclusions: We identified a significant 5-hmC loss in conjunctival melanoma similar to cutaneous melanoma. This loss may possibly be attributed to TET2 loss or IDH1 mutations. 5-hmC loss in conjunctival melanoma may help in the differential diagnosis between atypical conjunctival nevus and conjunctival melanoma. View Full-Text
Keywords: conjunctival melanoma; epigenetics; 5-hydroxymethylcytosine; 5-methylcytosine; TET2 conjunctival melanoma; epigenetics; 5-hydroxymethylcytosine; 5-methylcytosine; TET2
Show Figures

Figure 1

MDPI and ACS Style

Stahl, A.; Riggi, N.; Nardou, K.; Nicolas, M.; Kaya, G.; Moulin, A. 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma. Dermatopathology 2021, 8, 176-184.

AMA Style

Stahl A, Riggi N, Nardou K, Nicolas M, Kaya G, Moulin A. 5-Hydroxymethylcytosine Loss in Conjunctival Melanoma. Dermatopathology. 2021; 8(2):176-184.

Chicago/Turabian Style

Stahl, Alexandre, Nicolo Riggi, Katya Nardou, Michael Nicolas, Gurkan Kaya, and Alexandre Moulin. 2021. "5-Hydroxymethylcytosine Loss in Conjunctival Melanoma" Dermatopathology 8, no. 2: 176-184.

Find Other Styles

Article Access Map by Country/Region

Back to TopTop